On September 25, nearly $16.1 billion worth of Bitcoin options on Deribit expired, marking a significant quarterly event. However, the headline open interest figure does not represent the actual amount of money or Bitcoin exchanged at settlement, as it is a pre-expiry snapshot of outstanding contracts. The final settlement depends on the delivery price, contract types (BTC-settled or USDC-settled), and individual trader positions, which are not publicly detailed. Understanding the true financial impact requires final delivery prices, contract-level data, and clearing records, which are not yet available. This expiry clears contracts but does not directly translate to a $16.1 billion cash or Bitcoin transfer in the market.
Bitcoin options expiry is the story's subject, with Pluang market data providing context. As of Sep 25, 2026 18:22 WIB, 46 of 50 major cryptocurrencies rose while 3 fell. Notable movers include ALGO at Rp2.109 (+10.71%), COTI at Rp302 (+9.97%), and XNO at Rp6.814 (+9.11%).
Assured Guaranty Ltd. (NYSE: AGO) saw its stock price pressured to a new 52-week low of $68.04 despite a recent upgrade to "Buy" by Roth Capital. The company is involved in the financial restructuring of Brightline Florida, where a subsidiary insured...
Legacy Education Inc. reported Q4 2026 earnings with an EPS of $0.13, missing analyst estimates of $0.15, and revenue of $20.1 million, slightly below expectations. Despite this, the company achieved a 12% year-over-year revenue increase in Q4 and a ...
Carnival Corporation & plc is set to report Q3 earnings with analysts forecasting $8.39 billion in revenue and $1.36 EPS, reflecting a 4.9% decline from last year. The company's stock has dropped 27% recently due to a 30% surge in Brent oil prices, w...
Oklo, a pre-revenue nuclear tech company, is developing advanced small modular reactors (SMRs) called Aurora Powerhouses aimed at clean energy for data centers. UBS set a price target of $41, indicating a 7.08% upside from the current $38.29 stock pr...
Barclays initiated coverage on Ligand Pharmaceuticals with an 'Overweight' rating and set a price target of $345, implying a 15.37% upside from its current price. The biopharma company is expanding its royalty portfolio through investments in cancer ...
